CN106491834A - A kind of veterinary Chinese medicinal composition and its preparation method and application of granule - Google Patents
A kind of veterinary Chinese medicinal composition and its preparation method and application of granule Download PDFInfo
- Publication number
- CN106491834A CN106491834A CN201611126167.8A CN201611126167A CN106491834A CN 106491834 A CN106491834 A CN 106491834A CN 201611126167 A CN201611126167 A CN 201611126167A CN 106491834 A CN106491834 A CN 106491834A
- Authority
- CN
- China
- Prior art keywords
- parts
- group
- chinese medicine
- medicine
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000008187 granular material Substances 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 87
- 239000007788 liquid Substances 0.000 claims abstract description 51
- 238000001035 drying Methods 0.000 claims abstract description 39
- 239000000284 extract Substances 0.000 claims abstract description 20
- 239000002671 adjuvant Substances 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000009636 Huang Qi Substances 0.000 claims abstract description 12
- 210000000582 semen Anatomy 0.000 claims abstract description 11
- 241000287828 Gallus gallus Species 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 31
- 229940079593 drug Drugs 0.000 claims description 14
- 229920002472 Starch Polymers 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 230000036737 immune function Effects 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 238000005352 clarification Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 238000003809 water extraction Methods 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 239000002002 slurry Substances 0.000 claims description 3
- 238000005728 strengthening Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 abstract description 14
- 239000002245 particle Substances 0.000 abstract description 11
- 238000000605 extraction Methods 0.000 abstract description 10
- 238000012216 screening Methods 0.000 abstract description 7
- 229920001282 polysaccharide Polymers 0.000 abstract description 6
- 150000004676 glycans Chemical class 0.000 abstract description 5
- 239000005017 polysaccharide Substances 0.000 abstract description 5
- 208000026278 immune system disease Diseases 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000001914 filtration Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 36
- 230000000694 effects Effects 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 229960005486 vaccine Drugs 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 230000036039 immunity Effects 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 210000001541 thymus gland Anatomy 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 208000033065 inborn errors of immunity Diseases 0.000 description 8
- 230000002458 infectious effect Effects 0.000 description 8
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 8
- 238000003304 gavage Methods 0.000 description 7
- 244000144977 poultry Species 0.000 description 7
- 235000013594 poultry meat Nutrition 0.000 description 7
- 108010006464 Hemolysin Proteins Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000003228 hemolysin Substances 0.000 description 6
- 241000271566 Aves Species 0.000 description 5
- 208000027312 Bursal disease Diseases 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 210000001669 bursa of fabricius Anatomy 0.000 description 5
- 235000013330 chicken meat Nutrition 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 210000001539 phagocyte Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 241001484259 Lacuna Species 0.000 description 2
- 208000010359 Newcastle Disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- NULBHTHMVOCGOE-ZBCCAYPVSA-N 7-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-3-[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@H](OC=2C=C3C(C(C=C(O3)C=3C=CC(O)=CC=3)=O)=C(O)C=2)O1 NULBHTHMVOCGOE-ZBCCAYPVSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 206010004173 Basophilia Diseases 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 101100434911 Mus musculus Angpt1 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 208000004668 avian leukosis Diseases 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- STKUCSFEBXPTAY-KCWGXYKVSA-N nuezhenoside Natural products COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=CC)[C@@H]1CC(=O)OC[C@H]1O[C@@H](OCCc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O STKUCSFEBXPTAY-KCWGXYKVSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
This application discloses the preparation method and application of a kind of veterinary Chinese medicinal composition and its granule.Chinese medicine composition is by 40 parts of Fructus Ligustri Lucidi, 40 parts of the Radix Astragali, 10 parts of Fructus Lycii, 10 parts of Semen Cuscutae.Its preparation method includes：(1) research of extraction process by water, takes 40 parts of Fructus Ligustri Lucidi, and 40 parts of the Radix Astragali, 10 parts of Fructus Lycii, 10 parts of Semen Cuscutae carry out 3 decoctings and extract, and are concentrated into solid-liquid ratio 1:When 5, shell adding polysaccharide is clarified, and after filtration, is condensed into extractum.(2) selection of pharmaceutical drying condition, (1) gained extractum is dried, and is ground into medicated powder, crosses 60 mesh sieves.(3) screening of particle preparation condition, screens adjuvant, makes granule using single step.Chinese medicine composition of the present invention has functions that tonifying Qi and lifting yang, replenishing QI to invigorate the spleen, the medicine of enhancing chicken immuological function and treatment immune disease is can operate with, have the advantages that low production cost, reliable quality safety, colleges and universities' preventing and treating and immune disease and enhancing chicken immuological function.
Description
Technical field
The application belongs to medicine technology field, specifically, is related to the preparation of a kind of veterinary Chinese medicinal composition and its granule
Methods and applications.
Background technology
The disease that fowl poultry immune disease is Organism immunoregulation disequilibrium and causes immune response disorderly, animal
Immune system in body by immune organ (such as spleen, thymus, fabricius bursa etc.), immunocyte (as T lymphocytes, B lymphs thin
Born of the same parents, macrophage, erythrocyte etc.), cytokine (such as IL, TNF, antibody etc.) composition, three is by blood and the mutual ditch of body fluid
Logical, cooperate, play jointly the effect that safeguards body health and resist exopathogen invasion, as long as one part of any of which
Damage or defect can all cause the not normal of body's immunity, so as to cause the reduction or forfeiture of immunologic function, body by
Pathological changes are produced in protecting.If avian leukosis are that tumor change occur due to lymphocytes in blood, and then damage its immunity
System, affects the g and D of chicken group.This para-immunity disease often make the impaired development of fowl poultry immune system or
It is infected during late growing stage, easily causes the subinfection again such as antibacterial, virus, funguses, so as to forms multiple diseases simultaneously
Infection is sent out, the development of animal farming industry is had a strong impact on.
Chinese herbal medicine is natural organic matter and mineral, with toxic and side effects little, be not likely to produce drug resistance and in poultry body
The low feature of drug accumulation amount.Chinese medicine contains the effective ingredient such as substantial amounts of polysaccharide, flavone, alkaloid, not only can adjust poultry
The effect of immunologic function, moreover it is possible to which the effects such as participating in body disease-resistant poison, antibacterial, is mainly to develop and apply to substitute antibiotics at present
Key agents.In addition, Chinese medicine is again rich in abundant nutritional labeling, such as polysaccharide, protein, aminoacid, vitamin, digestion
Enzyme, trace element, sterol and hormone etc., can be good at enriched animal immune organ, promote which to develop so as to possess good
Opposing pathogen invasion.This is based on, Chinese herbal medicine is used for the immunologic function of enhancing body or some poultry Prevention of Infectious Diseases do not only have
Good drug effect, and use to improve as feed additive and livestock and poultry production performance and improve meat, Egg Quality, with embodying medicine
Effect globality and two big characteristics of medicine source natural sex.Surging with people's back to nature enthusiasm, Chinese herbal medicine is just with its uniqueness
Effect and feature are widely paid attention to.
Content of the invention
In view of this, technical problems to be solved in this application are to provide a kind of Chinese medicine composition and preparation, preparation method
And its application.
In order to solve above-mentioned technical problem, the application has opened a kind of veterinary Chinese medicinal composition, its include active component and/or
Pharmaceutically acceptable carrier, described active component contain following crude drug:Fructus Ligustri Lucidi, the Radix Astragali, Fructus Lycii, Semen Cuscutae.
Further, veterinary Chinese medicinal composition as above, the active component are made up of the raw material of following mass ratioes：
Fructus Ligustri Lucidi 10-80 parts, Radix Astragali 5-90 parts, Fructus Lycii 5-30 parts, Semen Cuscutae 5-30 parts.
Further, veterinary Chinese medicinal composition as above, the active component are made up of the raw material of following mass ratioes：
40 parts of Fructus Ligustri Lucidi, 40 parts of the Radix Astragali, 10 parts of Fructus Lycii, 10 parts of Semen Cuscutae.
The application also provides a kind of preparation method of veterinary Chinese medicine granule, comprises the following steps：
Step one：Veterinary Chinese medicinal composition is carried out water extraction；
Step 2：The extract that step one is obtained is dried；
Step 3：The preparation that dried for step 2 extract is carried out granule.
Further, method as above, the step one are comprised the following steps：
A, weigh Fructus Ligustri Lucidi, the Radix Astragali, Fructus Lycii, Semen Cuscutae in parts by mass, by solid-liquid ratio 1:10 add water, and soak 1h, decoct
1h is boiled, is filtered, is obtained medicinal liquid 1；
After b, step a, solid-liquid ratio 1 pressed by medicinal residues:8 add water, and decoct 1h, filter, obtain medicinal liquid 2；
After c, step b, solid-liquid ratio 1 pressed by medicinal residues:8 add water, and decoct 1h, filter, obtain medicinal liquid 3；
D, collection step a, b, c gained medicinal liquid carry out being concentrated into solid-liquid ratio 1:5,60 DEG C are cooled to, regulating liquid medicine pH is extremely
5.0, plus 0.01% chitosan solution carries out clarification 24h, is filtrated to get medicinal liquid；
E, step d gained medicinal liquid carry out being concentrated into solid-liquid ratio 1:1.
Further, method as above, the step 2 are comprised the following steps：By step e gained traditional Chinese drug inspissation thing
Adding carries out infrared microwave drying inside drying baker, temperature 60 C, the 1st section of microwave drying 0min, the 2nd section of microwave drying 20min,
3rd section of microwave drying 0min, the 4th section of microwave drying 0min, the 5th section of microwave drying 120min, the 6th section of microwave drying 120min,
7th section of microwave drying 60min, period see drying the medicinal liquid drying regime in case, prevent medicinal liquid from splashing, and drying is finished, and is taken out
Drying baker, is cooled to room temperature, takes out medicine, crushes, and crosses 60 mesh sieves, obtains Chinese medicine extract.
Further, method as above, the step 3 include：By the Chinese medicine extract for obtaining according to 1:2 add
Enter adjuvant, adjuvant is soluble starch：Microcrystalline Cellulose is 7 in mass ratio：3 mix, and make starch slurry with soluble powder,
150mL/min is whitewashed, and 100 DEG C carry out boiling granulating and drying, is arranged granule and is crossed No. 1 sieve, but No. 5 are sieved.
Application of the veterinary Chinese medicinal composition as above in the medicine for the treatment of immunologic function disease.
Application of the veterinary Chinese medicinal composition as above in the medicine for strengthening chicken immuological function.
Beneficial effect：
Chinese medicine composition disclosed by the invention, its formula are unique, and raw material is easy to get, low cost, are good for tonifying Qi and lifting yang, QI invigorating
Effect of spleen；The invention also discloses preparation prepared by Chinese medicine composition, its preparation method is simple, by Chinese medicine composition routinely
Method is extracted, infrared microwave drying is mixed with adjuvant, single step spray granulation is sent out and makes granule, is in solid dispersible carrier
High degree of dispersion state, increases the bioavailability of Chinese medicine composition；The traditional Chinese medicine particle of preparation can significantly improve chickling
Immune Organs Index, the content of IgG, IgA in serum improve Immune Profile In Chicks newcastle and the antibody after infectious bursa of Fabricius vaccine
Potency, and extend the lasting level of antibody.And the carbon clearance ability of hypoimmunity mice can be effectively improved, increase immune organ
Index and serum hemolysin, improve serum in IL-2, IL-4, the content of IFN-γ and reach strengthen immunologic function effect.
Description of the drawings
Accompanying drawing described herein is used for providing further understanding of the present application, constitutes the part of the application, this Shen
Schematic description and description please does not constitute the improper restriction to the application for explaining the application.In the accompanying drawings：
1 specnuezhenside standard substance canonical plotting of Fig. 1 embodiments；
1 specnuezhenside standard substance efficient liquid phase of Fig. 2 embodiments detection figure；
Fig. 3 embodiments 1 lack Fructus Ligustri Lucidi subsample (lacuna) efficient liquid phase detection figure；
Fig. 4 is 1 sample efficient liquid phase of embodiment detection figure.
Specific embodiment
Describe presently filed embodiment below in conjunction with drawings and Examples in detail, thereby how the application is applied
Technological means come solve technical problem and reach technology effect realize that process can fully understand and implement according to this.
For the immunomodulating of poultry, theoretical according to Chinese veterinarian's compound compatibility, filter out with Fructus Ligustri Lucidi, the Radix Astragali, Fructus Lycii,
Semen Cuscutae etc. with tonifying Qi and lifting yang, replenishing QI to invigorate the spleen Chinese medicine strengthening the immunologic function of chickling, carry out preventing and treating Immune Profile In Chicks and suppress
Property the disease Chinese medicine and its technique of compound preparation, quality standard, pharmacology pharmacodynamic research.
Embodiment 1, Chinese medicine composition effective substance method determine
Method：Detected using HPLC, with principal agent Fructus Ligustri Lucidi effective ingredient specnuezhenside as detection object.Chromatostrip
Part：C18 posts (46 × 150mm, 5 μm)；Mobile phase：Methanol-water (40:60)；Detection wavelength：224nm；Flow velocity：：1.0mL/min；
Column temperature：25℃；Standard solution is prepared：Precision weighs specnuezhenside in right amount, plus 50% methanol constant volume is configured to 10ml
0.25mg/ml concentration is obtained final product.Need testing solution is prepared：Accurate absorption test sample 2.0mL, 50% methanol solution are appropriate, at ultrasound
Reason 20min, takes out, lets cool to room temperature, then be settled to 50mL, shake up, and filters (0.22um), takes subsequent filtrate molten as test sample
Liquid.
Detection method：Accurate absorption reference substance solution and each 10 μ L of need testing solution, inject chromatograph of liquid, survey respectively
Fixed, obtain final product.
As a result：Accurate 2,4,6,8,10 μ L of absorption specnuezhenside reference substance solution, determine peak area according to above-mentioned chromatographic condition,
With peak area (Y) as vertical coordinate, the content (X, μ g) of special Fructus Ligustri Lucidi reference substance is abscissa, draws standard curve, and calculates recurrence
Equation：Y=1186.41048X-1.36851, R2=1.0000, as a result show, in the range of 0.4865-2.4325 μ g, special
Nuezhenoside integrating peak areas value y is linear good with content x, sees Fig. 1, Fig. 2, Fig. 3, Fig. 4.Precision is drawn the sample of 10 μ l and is lacked
Item injection efficient liquid phase is detected that sample specnuezhenside peak occurs in 6.655min, and lacuna does not go out in corresponding time point
Existing crest, the crest that remaining time point occurs are identical, illustrate that specnuezhenside content in the method detection sample has good special
Attribute.
Embodiment 2, Chinese medicine composition water extraction technical study
Method：Fructus Ligustri Lucidi is the principal agent in Chinese medicine composition, and specnuezhenside is its main labeled composition, therefore with special female
The content of loyal glycosides is inspection target, when decocting number of times, soak time, solid-liquid ratio, decoction with single factor test and orthogonal design screening
Between etc. process conditions.According to literature survey and practical experience, solid-liquid ratio is usually the 1 of medical material weight:8-1:12 times, investigate 1:8,
1:10,1:12 3 levels；Immersion 0,0.5, tri- levels of 1.0h is investigated, decocting time is oversize then to waste the energy, therefore specifies
0.5h, 1h, 1.5h are three times to investigate level；Decoct, number of times take too much oversize, therefore regulation 1,2,
Level is investigated for decocting number of times 3 times, respectively with single factor exploration each index, comprehensive the results of univariate logistic analysis, with soak time,
Solid-liquid ratio, decocting time are factor, carry out orthogonal test analysis using L9 (34).
Table 1 extracts test quadrature factor level
As a result：
(1) different extraction time results：Take Fructus Ligustri Lucidi 100g, respectively according to solid-liquid ratio be 1:10、1:8、1:8 amount adds
Water.Decocting and extract 3 times. each 1.0h, merging filtrate are concentrated into 100mL, determine the content for extracting specnuezhenside every time, knot respectively
Fruit shows that the content of specnuezhenside in medicinal liquid is raised with increasing for extraction time.
The selection of 2 extraction time of table
(2) different soak time result of the tests：Chinese medicine composition 100g is taken, totally 3 parts, be 1 according to solid-liquid ratio:10 amount adds
Hot water, soaks 0h, 0.5h, 1.0h respectively, filters, is concentrated into 100mL, determines respectively, as a result
Show that soak time can affect the content of specnuezhenside in medicinal liquid.
The screening of 3 medicine soak time of table
(3) different extraction time result of the tests：Chinese medicine composition 100g is taken, totally 3 parts, be 1 according to solid-liquid ratio:10 amount adds
Water, soaks 1h, decocts respectively and extracts 1.5h, 1.0h, 0.5h, filters, and is concentrated into 100mL, and measure is extracted specnuezhenside every time and contained
Amount, as a result shows that decocting time can affect the content of specnuezhenside in medicinal liquid.
The screening of 4 extraction time of table
(4) different feed liquid compares result of the test：Take Chinese medicine composition 100g, totally 3 parts, respectively according to solid-liquid ratio be 1:12、1:
10、1:8、1:6 amount adds water, and soaks 1 hour, decocts respectively and extract 1.0 hours, filter, be concentrated into 100mL, determines special Fructus Ligustri Lucidi
Glycosides content, as a result shows that solid-liquid ratio can affect the content of specnuezhenside in medicinal liquid.
Table 5 extracts the screening of amount of water
(5) orthogonal experiments：Test according to the arrangement of L9 (34) orthogonal table, water extraction is filtered, and is concentrated into 100mL, and measure is carried
Specnuezhenside content in liquid is taken, result of the test is through range analysiss C (decocting time) ＞ B (solid-liquid ratio) ＞ A (soak time), and C2
＞ C1 ＞ C3, B3 ＞ B1 ＞ B2, A3 ＞ A1 ＞ A2.The results of analysis of variance shows, difference not significantly (＜ between three factors
0.05) real cost of production and time is combined therefore, extraction process is determined for A3B3C2, i.e. immersion 1h, decoction three times, every time
Solid-liquid ratio is respectively 1:10、1:8、1:8, decoct 1h every time.
6 orthogonal experiments of table
7 the results of analysis of variance of table
* Significant effect F 0.05 (2,2)=19.0
Embodiment 3, the screening of clarification factor level
Method：According to screening gained extraction process carry out extract 9 parts of Chinese medicine composition, every part of 100g, according to L9 (34) just
Table arrangement is handed over, with clear and bright dose of 1% chitosan solution, the addition of shitosan, fluid temperature, medicinal liquid pH is investigated, designed
Factor level table.
8 clearance quadrature factor level of table
As a result：Test according to the arrangement of L9 (34) orthogonal table, clarified using 1% shitosan, 5000r/min is centrifuged
10min, counts the weight of precipitate, and as a result range analysiss show B (fluid temperature) ＞ C (medicinal liquid pH) ＞ A (interpolations of shitosan
Amount), and B3 ＞ B2 ＞ B1, C1 ＞ C2 ＞ C3, A2 ＞ A3 ＞ A1, the results of analysis of variance show that difference does not show between three factors
Write (＜ 0.05), accordingly, it is determined that it is 60 DEG C that clarification condition is B3C1A2, i.e. fluid temperature, during pH5.0, add 0.10% shell
Polysaccharide solution is clarified.
9 orthogonal experiments of table
10 the results of analysis of variance of table
* Significant effect F 0.05 (2,2)=19.0
The selection of embodiment 4, ratio of adjuvant
For the ease of storing and carrying, easy to use, the extract of Chinese medicine composition is made and various is controlled suitable for clinic
The preparation for needing is treated, acceptable carrier on pharmaceuticss can be added in the formulation, the method for preparation is conventional method.Such as by medium-height grass
Various Chinese crude drugs in drug composition are directly ground to fine powder, make powder, or add binding agent to make pill；Or by medium-height grass
The extract of drug composition makes capsule, tablet, granule etc. with acceptable carrier on pharmaceuticss.These extracts and preparation
There is identical therapeutical effect with herbal composite.So the Chinese medicine composition of test and Selection makes granule, granule is commonly used
Adjuvant has starch, Icing Sugar, dextrin, Microcrystalline Cellulose and soluble starch etc..Due to Icing Sugar pelleting moisture absorption stronger, therefore not
Use Icing Sugar.
Method：Added with 3 gained medicine of embodiment infrared microwave drying, temperature is carried out inside the drying baker of 40cm*50cm
60 DEG C, the 2nd section of microwave drying 20min, the 5th section of microwave drying 120min, the 6th section of microwave drying 120min, the 7th section of microwave drying
60min, period see drying the medicinal liquid drying regime in case, prevent medicinal liquid from splashing, and drying is finished, and is taken out drying baker, is cooled to
Room temperature, takes out medicine, crushes, sieves, obtain Chinese medicine extract.Take extract in right amount, add the adjuvants of 2 times of amounts, mix respectively
Uniformly, starch slurry is made with soluble powder, 150mL/min is whitewashed, carry out boiling granulating and drying according to 100 DEG C, arrange
Granule crosses No. 1 sieve, but No. 5 are sieved, and the mouldability for investigating granule determines adjuvant used, selectes molding with mouldability as inspection target
Adjuvant.
As a result：With soluble starch as adjuvant pelletize when, soft material stickiness is larger, is difficult to sieve.During with dextrin as adjuvant, auxiliary
Material hygroscopicity is poor, is difficult to pelletize.Accordingly, it is considered to use soluble starch and microcrystalline cellulose fibres element mixing as adjuvant.And
And the increase with Microcrystalline Cellulose materials, the mouldability of granule improves, but as soluble starch is compared with Microcrystalline Cellulose cost
Low, it is thus determined that adjuvant is soluble starch：Microcrystalline Cellulose is 7：3.
The selection of 11 ratio of adjuvant of table
Embodiment 5, traditional Chinese medicine particle causes hypoimmunity mice immunomodulating to cyclophosphamide
According to 4 result of embodiment, it is dissolved as suspension shape and is carried out as follows enforcement.
Mice is randomly divided into 6 groups, respectively basic, normal, high dose of blank group, model group, positive drug group, Chinese medicine composition
Amount group, 20 per group, does 1 repetition, compares according to EXPERIMENTAL DESIGN, blank group and model group gavage normal saline per group, in
The basic, normal, high dosage group chickling of drug composition presses 0.5g/kg, and 1.0g/kg, 2.0g/kg gavage traditional Chinese medicine particle is used in conjunction 7
My god, once a day, positive controls are experimental control according to operation instruction feeding astragalus polysaccharidess, when being administered the 4th day, except blank
Group is outer, and other every group of mice is according to 60mg/kg intraperitoneal injection of cyclophosphamide 1 time.
(1) mice phagocyte imdex determination test
Method：After each group mice last dose 24h, each repeats to randomly select 6, totally 12, with 0.1mL/10g body weight
Dosage, the india ink after tail vein injection process, after injection 2,10min respectively with the suction pipe processed through heparin, from little
Rathole vena orbitalis posterior takes 20 μ L of blood, is blown into the Na that 2mL mass fractions are 0.1% immediately2CO3Shake up in solution, take after blood is finished with
Mass fraction is 0.1% Na2CO3Solution surveys absorbance (OD) compared with zero in 650nm, calculates phagocyte imdex (K) and correction
Clean up index (α).
K=(lgA1- lgA2)/(t2- t1)
α=K1/3Body weight/(liver weight+spleen weight)
(A in formula1、A2For the absorbance that 2 institute's blood-sample withdrawals of priority are measured, t2- t1Time interval for 2 blood samplings.)
As a result：After mouse peritoneal injection cyclophosphamide, extremely significantly (P ＜ 0.01) is less than blank group, gavage to phagocyte imdex
Significantly raise (P ＜ 0.01) compared with model group after medicine, and dosage is better than 0.5g/kg for the effect of 2.0g/kg and 1.0g/kg, its
Between diversity significantly (0.01 ＜ P ＜ 0.05).
12 traditional Chinese medicine particle of table is affected on hypoimmunity mice phagocyte imdex
Note：The different lower case person significant difference (P of colleague's shoulder mark<0.05), different capitalization person differences extremely significantly (P<
0.01), without alphabetical person or the not notable (P of alphabetical identical person's difference>0.05).
(2) determination test of serum hemolysin
Method：After being administered the 7th day, each repeats to randomly select 6, totally 12, respectively lumbar injection 5%CRBC suspensions
0.2mL carries out immunity, immune 7 days, and after last dose 24h, eyeball is taken a blood sample, and separates serum.Serum normal saline is taken after centrifugation
100 times of dilution.Serum 1mL and 5%CRBC suspension 0.5mL, 10% complement 0.5mL after dilution is taken, is mixed, in 37 DEG C of calorstats
30min is after 0 DEG C of refrigerator (or in ice-water bath) terminating reaction for insulation.Supernatant is taken in ultraviolet spectrometry after 2000rpm centrifugation 10min
Absorbance A is measured at photometer 540nm, and the value of hemolysin is with half hemolysis value HC50Represent.HC50=(sample absorbance value/
Absorbance during CRBC HD50s) × extension rate.
As a result：Model group mice serum hemolysin HC50Extremely significantly (P ＜ 0.01) reduces；After gavage Chinese medicine composition,
1.0g/kg dosage groups effect is better than 2.0g/kg and 0.5g/kg dosage groups, and significant difference compared with 0.5g/kg dosage groups
(0.01 ＜ P ＜ 0.05).
13 traditional Chinese medicine particle of table is affected on hypoimmunity mice serum hemolysin
Note：The different lower case person significant difference (P of colleague's shoulder mark<0.05), different capitalization person differences extremely significantly (P<
0.01), without alphabetical person or the not notable (P of alphabetical identical person's difference>0.05).
(3) in mice serum cytokine measure
Method：Each repeats to randomly select 6, and totally 12, after last dose 24h, eyeball takes blood, is prepared into serum,
Carry out detecting corresponding index according to each kit specification respectively.
As a result：Model group mice IL-2, IL-4, IFN-γ content substantially reduce, after test, traditional Chinese medicine particle and
In positive drug group serum, higher than model group (P ＜ 0.01), IL-2 contents are raised not enough substantially, with mould for IL-4, IFN-γ content
Type group compares difference not significantly (P ＞ 0.05).
Impact of 14 traditional Chinese medicine particle of table to IL-2, IL-4, IFN-γ content in hypoimmunity mice serum
Note：The different lower case person significant difference (P of colleague's shoulder mark<0.05), different capitalization person differences extremely significantly (P<
0.01), without alphabetical person or the not notable (P of alphabetical identical person's difference>0.05).
(4) measure of mouse immune shoot formation
Method：To gather at the mice dislocation of blood, taken spleen and thymus, claim its quality, spleen index has been calculated by formula
And thymus index.Index and spleen index=spleen/body weight；Thymus index=thymus/body weight.
As a result：Model group mouse spleen index and thymus index have downward trend, and compared with blank group, difference is extremely notable
(P ＜ 0.01)；After gavage Chinese medicine, mouse spleen index is significantly raised, and in the range of finite concentration, has obvious dose-effect to close
System；Thymus index also increases, and its drug concentration is that 1.0g/kg effects are preferable, significant difference compared with 0.5g/kg groups
(0.01 ＜ P ＜ 0.05).
15 traditional Chinese medicine particle of table is affected on hypoimmunity mice Immune Organs Index
Note：The different lower case person significant difference (P of colleague's shoulder mark<0.05), different capitalization person differences extremely significantly (P<
0.01), without alphabetical person or the not notable (P of alphabetical identical person's difference>0.05).
Embodiment 6, traditional Chinese medicine particle causes hypoimmunity mice immunomodulating to cyclophosphamide
According to 4 result of embodiment, it is dissolved as suspension shape and is carried out as follows enforcement.
Test 3 age in days, 180 plumage SPF chickling is randomly divided into 6 groups, respectively blank group, positive controls, vaccine group, height,
In, low dose group, per group of 30 plumages, adapt to 3 days after, according to EXPERIMENTAL DESIGN, basic, normal, high dosage group chickling presses 0.5g/kg,
1.0g/kg, 2.0g/kg gavage Chinese medicine compositions are used in conjunction 7 days, daily 2 times, and positive controls feed the Radix Astragali according to operation instruction
Polysaccharide is experimental control, per 10 plumage of cage, equal free water and feeding, feeds identical basal diet.
(1) impact to growth performance
Method：At on-test, measurement each group chickling all the time, was weighed to chickling every 7 days respectively, test knot
The indexs such as weightening, daily gain and the feed-weight ratio of each group chickling are calculated after beam, is observed per plumage chickling in units of cage during test
Clinical change.
As a result：Before test, not significantly (P ＞ 0.05), after test 35 days, high dose group is with for each group chickling weight differences
The body weight of dosage group chickling is significantly raised, significant difference (P ＜ 0.05) compared with blank group；As can be seen from Table 17, middle dose
The weightening of amount group chicken feed is than substantially reduction, significant difference (P ＜ 0.05) compared with blank group.
16 each test group chickling of table body weight change (unit not on the same day：Gram)
Body weight change (the unit not on the same day of table 17：Gram)
Note：The different capitalizations of same row shoulder mark represent, P ＜ 0.01, different lowercase letter P ＜ 0.05, do not mark or
Person's table same letter represents P ＞ 0.05.
(2) impact to hematological indices
Method：Every 7 days before immunity and after immunity, jugular vein gathers 200 μ L of blood to each group chickling, for detecting
Hematological indices, erythrocyte, numeration of leukocyte adopt microscope count method；Differential blood count is using Rui Shi-Jim Sa dye
Color method.
As a result：In test group chickling blood, erythrocyte number gradually rises, and assumes a certain amount effect relation, leukocyte count
Amount, neutrophilia, acidophilia, basophilia, amount of mononuclear cells do not have significance change (P ＞ 0.05), and high, middle dose group lymph is thin
Born of the same parents are significantly higher than blank group (P ＜ 0.05).
The change of 18 each test group chickling hemocyte of table
Note：The different capitalizations of same row shoulder mark represent, P ＜ 0.01, different lowercase letter P ＜ 0.05, do not mark or
Person's table same letter represents P ＞ 0.05.
(3) impact to Immune Organs Index
Method：After administration 2 weeks, per group of 10 plumage SPF chickens of random selection claim its body weight, after collection blood, take spleen, breast
Gland and fabricius bursa, peel off fat, claim quality, calculate spleen, thymus and bursal index by formula, calculate organ index.Immune device
Official's index=immune organ quality/body weight × 100%.
As a result：High, medium and low dosage group index and spleen index, thymus index and bursal index increase, middle dose group breast
Gland index significant difference (P ＜ 0.05) compared with blank group and low dose group with bursal index.
Change (the unit of 19 each test group Immune Organs Index of Chicks of table：mg/g)
Note：The different capitalizations of same row shoulder mark represent, P ＜ 0.01, different lowercase letter P ＜ 0.05, do not mark or
Person's table same letter represents P ＞ 0.05.
(4) impact to chicken Newcastle disease antibody horizontal
Method：Identical administration is carried out according to test requirements document, head on the 7th exempts from newcastle disease vaccine in addition to blank group, 30
Secondary immunity.Every 7 days before immunity and after immunity, jugular vein gathers blood 2mL to each group chickling, separates serum, adopts
Blood clotting, hemagglutination inhibition test, detect ND antibody horizontals.
As a result show：The non-vaccination of chickling, antibody titres to newcastle disease virus have the trend of reduction, post-vaccine antibody potency
It is obviously improved, on 14th, vaccinated chickling raised (P ＜ 0.05) with blank group chickling antibody titer significant difference, respectively
Medicine group antibody titer is also significantly greater than vaccine group (P ＜ 0.05), and on 21st, each medicine group chickling also still kept higher
Antibody titer, and vaccine group and blank group significant difference (P ＜ 0.05), in second vaccination, the antibody titer of medicine group
Pole is significantly higher than blank group (P ＜ 0.01), 42, and high dose group and middle dose group chickling antibody titer are significantly higher than vaccine group
With positive drug group (P ＜ 0.05), and middle dosage effect is best.
The change (log2) of 20 each group chickling ND antibody titers of table
Note：The different capitalizations of same row shoulder mark represent, P ＜ 0.01, different lowercase letter P ＜ 0.05, do not mark or
Person's table same letter represents P ＞ 0.05.
(5) impact to infectious avian bursal disease virus antibody titer
Method：Identical administration is carried out according to test requirements document, head on the 14th exempts from IBD vaccines in addition to blank group, 32 days two
Secondary immunity.Every 7 days before immunity and after immunity, jugular vein gathers blood 2mL to each group chickling, separates serum, agarose
Diffusion method (AGPT) detects IBD antibody horizontals.
As a result：Before test, each group infectious avian bursal disease virus antibody positive rate is in the range of 34.8-40%, poor between group
Different significantly (P ＞ 0.05) during being administered, each group chickling antibody positive rate does not reduce, but not notable (the P ＞ of group difference
0.05), 21 days when, medicine group antibody positive rate is significantly raised, and difference extremely significantly (P ＜ 0.01), also shows compared with blank group
It is higher than vaccine group (P ＜ 0.05) to write；When 28 days, antibody has declined, but medicine group antibody positive rate is significantly higher than blank
Group and vaccine group (P ＜ 0.05)；After two exempt from, medicine high dose group and middle dose group positive rate reach 100%, poor with vaccine group
Different notable (P ＜ 0.05), with blank group difference extremely significantly (P ＜ 0.01)；When 42 days, medicine group all reaches 100%, vaccine group
92.2% is only reached, with blank group difference extremely significantly (P ＜ 0.01).
21 each group infectious avian bursal disease virus antibody positive rate of table
Note：Represent with the different capitalizations of a line shoulder mark, P ＜ 0.01, different lowercase letter P ＜ 0.05, do not mark or
Person's table same letter represents P ＞ 0.05.
As a result：When before test with 14 days, each group infectious avian bursal disease virus antibody titer group difference is not notable
(P ＞ 0.05), first immunity Seedling 7 days (21 age in days), antibody titer are significantly higher than blank group (P ＜ 0.05), antibody effect when 28 days
Valency has reduction trend, presents a certain amount effect relation, after 35 days, positive drug group and high, middle dose group antibody titer pole
Blank group and vaccine group (P ＜ 0.01) is significantly higher than, after 35 days, high, medium and low dosage group antibody titer pole is significantly higher than sky
White group and vaccine group (P ＜ 0.01),
The change of 22 each group infectious avian bursal disease virus antibody titer of table
Note：The different capitalizations of same row shoulder mark represent, P ＜ 0.01, different lowercase letter P ＜ 0.05, do not mark or
Person's table same letter represents P ＞ 0.05.
Conclusion
Modern pharmacological research shows, Chinese medicine prevent and treat immune disease and strengthen Immune Function In Animals application in, medicine
Should be nontoxic as far as possible, damage of the medicine to histoorgan is reduced while disease is treated.Chinese medicine ingredients are complicated simultaneously
Various, in order to be able to accurately study the effect of medicine, set up a perfect extraction and preparation technique and supporting examination criteria seems
Particularly important.
From single factor test and orthogonal test, this test determines that Chinese medicine composition water extraction condition, orthogonal test determine clarification condition,
Granule preparation condition, sets up a perfect extraction process and its supporting detection method.And by giving injected in mice ring phosphinylidyne
Amine sets up immunodeficiency models, and gavage Chinese medicine composition carries out immunocompetence research；Add Chinese medicine group in chickling drinking-water simultaneously
Polymer beads, detect growth performance of the Chinese medicine composition to chickling, the impact of newcastle and infectious bursa of Fabricius antibody titer.Knot
Fruit shows that traditional Chinese medicine particle can effectively improve the carbon clearance ability of hypoimmunity mice, increase Immune Organs Index and
Serum hemolysin, improve serum in IL-2, IL-4, the content of IFN-γ and reach strengthen immunologic function effect；And significantly
The Immune Organs Index of chickling is improved, the content of IgG, IgA in serum improves Immune Profile In Chicks newcastle and infectious bursa of Fabricius epidemic disease
The antibody titer of after seedling, and extend the lasting level of antibody.
Described above illustrates and describes some preferred embodiments of the present invention, but as previously mentioned, it should be understood that the present invention
Be not limited to form disclosed herein, be not to be taken as the exclusion to other embodiment, and can be used for various other combinations,
Modification and environment, and can be in invention contemplated scope described herein, by above-mentioned teaching or the technology or knowledge of association area
It is modified.And change that those skilled in the art are carried out and change be without departing from the spirit and scope of the present invention, then all should be at this
In the protection domain of bright claims.
Claims (9)
1. a kind of veterinary Chinese medicinal composition, which includes active component and/or pharmaceutically acceptable carrier, it is characterised in that institute
The active component that states contains following crude drug:Fructus Ligustri Lucidi, the Radix Astragali, Fructus Lycii, Semen Cuscutae.
2. veterinary Chinese medicinal composition according to claim 1, it is characterised in that the active component is by following mass ratioes
Raw material is constituted：Fructus Ligustri Lucidi 10-80 parts, Radix Astragali 5-90 parts, Fructus Lycii 5-30 parts, Semen Cuscutae 5-30 parts.
3. Chinese medicine composition according to claim 1, it is characterised in that raw material of the active component by following mass ratioes
Composition：40 parts of Fructus Ligustri Lucidi, 40 parts of the Radix Astragali, 10 parts of Fructus Lycii, 10 parts of Semen Cuscutae.
4. a kind of preparation method of veterinary Chinese medicine granule, it is characterised in that comprise the following steps：
Step one：Veterinary Chinese medicinal composition is carried out water extraction；
Step 2：The extract that step one is obtained is dried；
Step 3：The preparation that dried for step 2 extract is carried out granule.
5. method according to claim 4, it is characterised in that the step one is comprised the following steps：
A, weigh Fructus Ligustri Lucidi, the Radix Astragali, Fructus Lycii, Semen Cuscutae in parts by mass, by solid-liquid ratio 1:10 add water, and soak 1h, decoct 1h,
Filter, obtain medicinal liquid 1；
After b, step a, solid-liquid ratio 1 pressed by medicinal residues:8 add water, and decoct 1h, filter, obtain medicinal liquid 2；
After c, step b, solid-liquid ratio 1 pressed by medicinal residues:8 add water, and decoct 1h, filter, obtain medicinal liquid 3；
D, collection step a, b, c gained medicinal liquid carry out being concentrated into solid-liquid ratio 1:5, be cooled to 60 DEG C, regulating liquid medicine pH to 5.0, plus
0.01% chitosan solution carries out clarification 24h, is filtrated to get medicinal liquid；
E, step d gained medicinal liquid carry out being concentrated into solid-liquid ratio 1:1.
6. method according to claim 5, it is characterised in that the step 2 is comprised the following steps：By in step e gained
Medicine concentrate is added and carries out infrared microwave drying inside drying baker, temperature 60 C, the 1st section of microwave drying 0min, and the 2nd section of microwave is done
Dry 20min, the 3rd section of microwave drying 0min, the 4th section of microwave drying 0min, the 5th section of microwave drying 120min, the 6th section of microwave drying
120min, the 7th section of microwave drying 60min, period see drying the medicinal liquid drying regime in case, prevent medicinal liquid from splashing, have dried
Finish, take out drying baker, be cooled to room temperature, take out medicine, crush, cross 60 mesh sieves, obtain Chinese medicine extract.
7. method according to claim 6, it is characterised in that the step 3 includes：By the Chinese medicine extract for obtaining
According to 1:2 add adjuvant, and adjuvant is soluble starch：Microcrystalline Cellulose is 7 in mass ratio：3 mix, and make shallow lake with soluble powder
Slurry, 150mL/min are whitewashed, and 100 DEG C carry out boiling granulating and drying, arrange granule and cross No. 1 sieve, but No. 5 are sieved.
8. application of the veterinary Chinese medicinal composition described in claim 1 in the medicine for the treatment of immunologic function disease.
9. application of the veterinary Chinese medicinal composition described in claim 1 in the medicine for strengthening chicken immuological function.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611126167.8A CN106491834A (en) | 2016-12-09 | 2016-12-09 | A kind of veterinary Chinese medicinal composition and its preparation method and application of granule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611126167.8A CN106491834A (en) | 2016-12-09 | 2016-12-09 | A kind of veterinary Chinese medicinal composition and its preparation method and application of granule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106491834A true CN106491834A (en) | 2017-03-15 |
Family
ID=58330611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611126167.8A Pending CN106491834A (en) | 2016-12-09 | 2016-12-09 | A kind of veterinary Chinese medicinal composition and its preparation method and application of granule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106491834A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107543893A (en) * | 2017-08-24 | 2018-01-05 | 重庆市畜牧科学院 | The discrimination method of Semen Cuscutae in a kind of female's Huang Zheng oral liquid |
| CN109893642A (en) * | 2019-04-16 | 2019-06-18 | 重庆市畜牧科学院 | The Chinese medicine composition for treating grice diarrhoea |
| CN111135251A (en) * | 2020-01-09 | 2020-05-12 | 山西中医药大学 | Veterinary drug for preventing and treating chicken bursal disease as well as preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101698027A (en) * | 2009-10-30 | 2010-04-28 | 重庆市畜牧科学院 | Traditional Chinese medicine composite for treating infectious bursal disease and preparation method thereof |
-
2016
- 2016-12-09 CN CN201611126167.8A patent/CN106491834A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101698027A (en) * | 2009-10-30 | 2010-04-28 | 重庆市畜牧科学院 | Traditional Chinese medicine composite for treating infectious bursal disease and preparation method thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107543893A (en) * | 2017-08-24 | 2018-01-05 | 重庆市畜牧科学院 | The discrimination method of Semen Cuscutae in a kind of female's Huang Zheng oral liquid |
| CN109893642A (en) * | 2019-04-16 | 2019-06-18 | 重庆市畜牧科学院 | The Chinese medicine composition for treating grice diarrhoea |
| CN111135251A (en) * | 2020-01-09 | 2020-05-12 | 山西中医药大学 | Veterinary drug for preventing and treating chicken bursal disease as well as preparation method and application thereof |
| CN111135251B (en) * | 2020-01-09 | 2021-11-26 | 太原市恩禾动物药业有限公司 | Veterinary drug for preventing and treating chicken bursal disease as well as preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101310751B (en) | Detection method of medicine composition for replenishing qi and blood | |
| US10813961B2 (en) | Powder formulation having a function of enhancing immunity and method for preparing the same | |
| CN112535239B (en) | Compound Chinese herbal medicine feed additive for daily health care and growth promotion of livestock and preparation and application thereof | |
| CN111135251B (en) | Veterinary drug for preventing and treating chicken bursal disease as well as preparation method and application thereof | |
| CN106491834A (en) | A kind of veterinary Chinese medicinal composition and its preparation method and application of granule | |
| CN105148258A (en) | Composition and application thereof, and preparation containing composition | |
| CN103083510A (en) | Chinese medicinal oral liquid for improving poultry immune function and its preparation method | |
| CN104288217A (en) | Traditional Chinese medicine composition and application thereof | |
| CN104800370A (en) | Herbal injection for treating pig's blue-ear disease | |
| CN101926861A (en) | Method for preparing Chinese medicinal veterinary medicament for enhancing non-specific immune function | |
| CN103735621B (en) | A kind of Chinese medicine composition with blood fat reducing and enhancing immunity effect | |
| CN103860656A (en) | Traditional Chinese medicinal composition, and preparation method and application thereof | |
| CN100558343C (en) | Chinese medicine preparation of the liver soothing and the spleen invigorating and preparation method thereof | |
| CN102764294A (en) | Cough relieving and sputum eliminating combination and preparation method thereof | |
| CN101912452A (en) | Veterinary Chinese medicinal composition for enhancing nonspecific immunologic function and application thereof | |
| CN102100730B (en) | Traditional Chinese medicine for improving poultry immunity | |
| CN104367673B (en) | A kind of Chinese medicine composition treating Eimeria species | |
| CN1977886B (en) | Medicinal composition of oxymatrine, ganoderma lucidum and astragalus | |
| CN110559415B (en) | Natural plant compound preparation for improving young bird breeding rate and preparation method and application thereof | |
| CN100493522C (en) | Medicinal composition of oxymatrine and polysaccharide | |
| CN1686424A (en) | Medicinal composition containing scutellaria and bupleurum and its preparation method | |
| CN108208411B (en) | Metabolism immunoregulation composite solution for livestock and poultry and preparation method thereof | |
| CN1970001B (en) | Pharmaceutical composition comprising kurarinone, magnolia vine fruit and ginseng for treating hepatitis | |
| CN104758719B (en) | A kind of Chinese medicine composition, granule and preparation method for treating leukopenia | |
| CN106421085A (en) | Paulownia flower-containing pharmaceutical composition for treating animal viral infectious diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170315 |